证券代码：301080 证券简称：百普赛斯 公告编号：2024-018 北京百普赛斯生物科技股份有限公司 关于公司高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）董事会于近日收 到公司副总经理陈劲秋女士的书面辞职报告，陈劲秋女士因个人原因申请辞去公 司副总经理职务，辞职后陈劲秋女士将不再担任公司任何职务。根据《公司法》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等相关规定，陈劲秋女士的辞职申请自送达董事会之日起生效。 陈劲秋女士原定任期至第二届董事会届满之日止。截至本公告日，陈劲秋女 士未持有公司股份，亦不存在应当履行而未履行的承诺事项。 陈劲秋女士在任期间对公司产品及应用开发做出重要贡献，公司董事会对陈 劲秋女士勤勉尽责的工作及为公司发展做出的贡献表示衷心感谢！ 陈劲秋女士的辞职不会影响公司相关工作的正常进行。 特此公告。 北京百普赛斯生物科技股份有限公司董事会 2024 年 5 月 17 日 ...

[Table_Reports] 重点研究上市公司： 天士力,华润三九,人福医药,凯莱英,纳微科技,药康生物,方盛制药,片仔癀,华兰生物,同仁堂,太极集团,微芯生物,康 泰生物,康龙化成,一品红,迈瑞医疗,贝达药业,百普赛斯,诺唯赞,惠泰医疗,诺禾致源,普瑞眼科,英诺特,以岭药业,鱼 跃医疗,科伦药业,泰格医药,东阿阿胶,万孚生物,康华生物 投资评级说明 | --- | --- | --- | --- | |----------------------------------------------------------------|------------|----------|-----------------------------------------------------------| | 1. 投资评级的比较和评级标准： | 类 别 | 评 级 | 说 明 | | 以报告发布后的 6 个月内的市场表现 | | 优于大市 | 预期个股相对基准指数涨幅在 10% 以上； | | 为比较标准，报告发布日后 6 个月内 | 股票投资评 | 中性 | 预期个股相对基准指数涨幅介于 -10% 与 10% ...

Investment Rating - The report assigns a "Buy" rating to the company, with a target price of 51.73 CNY per share based on a reasonable PE of 38 times for 2024 [1][23]. Core Insights - The company reported a revenue of 544 million CNY in 2023, representing a year-on-year growth of 14.59%. However, the net profit attributable to shareholders decreased by 24.61% to 154 million CNY due to increased personnel costs and depreciation [3][21]. - The overseas conventional business continues to grow significantly, with a 37% year-on-year increase in overseas conventional business revenue, while the overall conventional business revenue (excluding specific acute respiratory disease-related products) grew by 29% [3][21]. - The company is actively expanding its clinical business, having developed nearly 30 high-quality GMP-grade products, which are expected to generate substantial demand as projects progress to clinical stages [3][21]. Financial Summary - The company’s revenue is projected to reach 630 million CNY in 2024, with a growth rate of 15.9%. The net profit is expected to recover slightly to 163 million CNY, reflecting a growth rate of 6.4% [21][22]. - The earnings per share (EPS) is forecasted to be 1.36 CNY in 2024, with a PE ratio of 32.64 [22][23]. - The gross margin for 2023 was 91.26%, with a net profit margin of 27.12%, indicating a decline in profitability primarily due to increased sales and management expenses [3][21].

Investment Rating - The investment rating for the company is "Buy" with a maintained rating for the next six months [4]. Core Views - The company reported a revenue of 544 million yuan in 2023, representing a year-on-year growth of 14.59%, while the net profit attributable to the parent company decreased by 24.61% to 154 million yuan [2][7]. - The first quarter of 2024 saw a revenue of 146 million yuan, a year-on-year increase of 6.67%, but the net profit attributable to the parent company dropped by 31.91% to 31 million yuan [2]. - Excluding specific acute respiratory disease-related products, the sales revenue reached 139 million yuan in Q1 2024, marking a 16% year-on-year growth [3]. Financial Performance - The company has shown a consistent growth trend in its regular business, with a 29.46% increase in sales revenue, excluding specific acute respiratory disease-related products, reaching 499 million yuan in 2023 [5][14]. - R&D expenses increased by 9.72% to 125 million yuan in 2023, with the number of R&D personnel growing by 30.69% to 247 [6]. - The revenue forecast for 2024 has been adjusted down from 863 million yuan to 626 million yuan, with the net profit forecast reduced from 345 million yuan to 172 million yuan [7]. Product Development - The company is expanding its product portfolio in cell and gene therapy, companion diagnostics, clinical sample analysis, and clinical medication monitoring [3]. - A series of recombinant proteins and unique antibodies targeting CD19, BCMA, and Her2 have been developed, with nearly 30 high-quality GMP-grade products launched [3][15]. Financial Projections - The projected revenue for 2024 is 626 million yuan, with expected growth rates of 15.23% in 2024, 21.23% in 2025, and 20.56% in 2026 [20]. - The net profit attributable to the parent company is expected to be 172 million yuan in 2024, with projections of 201 million yuan in 2025 and 233 million yuan in 2026 [20].

[Table_TargetPrice] ——百普赛斯(301080.SZ)2023 年及 2024 一季度报告点评 [Table_Main] 公司研究|医疗保健|制药、生物科技与生命科学 证券研究报告 百普赛斯(301080)公司点评报告 2024 年 04 月 27 日 [Table_Title] 特定干扰渐见底，海外持续高增长 [Table_Summary] 事件： 百普赛斯于近日发布 2023 年报及 2024 一季度报告：2023 年公司实现收 入 5.44 亿（+14.59%），归母净利润 1.54 亿（-24.61%），扣非归母净利润 1.40 亿（-23.42%）。分季度看，2023Q4 收入 1.31 亿（+7.57%），归母净 利润 0.25 亿（-33.02%），扣非归母净利润 0.16 亿（-49.35%）；2024Q1 收 入 1.46 亿（6.67%），归母净利润 0.31 亿（-31.91%），扣非归母净利润 0.30 亿（-32.12%）。 特定急性呼吸道传染病相关收入影响快速下降，海外持续高增长 分疾病应用领域看，2023 年特定急性呼吸道传染病相关产品收入 0.45 亿 （- ...

医药生物/生物制品 投资评级：买入（维持） -64% -48% -32% -16% 0% 16% 2023-04 2023-08 2023-12 2024-04 百普赛斯 沪深300 《收入端增长稳健，海外市场开拓打 开成长空间—公司信息更新报告》 -2023.11.17 ——公司信息更新报告 公司常规业务维持高增长，海外收入增速亮眼 隐证券 百普赛斯（301080.SZ） 2024 年 04 月 26 日 股价走势图 相关研究报告 常规业务持续高增长，高费用影响短期利润 2023 年业绩稳健增长，2024 年 Q1 增速有所放缓，高费用影响短期利润 公司 2023 年常规业务收入 5.00 亿元，同比增长 29.5%；2024 年 Q1 常规业务收 入 1.38 亿元，同比增长 16.0%。2023 年公司进一步挖掘国际市场，在欧洲和日 本等地新设多家海外子公司，目前销售网络已经覆盖北美、亚太及欧洲等主要国 家和地区。2023 年海外常规业务收入 3.3 亿元，同比增长 37.0%，占比 66.1%。 其中，2023 年美洲区常规业务收入 2.29 亿元，同比增长 29.8%；欧洲区常规业 务收入 0.72 ...

[ T able_StockInfo] 2024 年 04 月 24 日 证券研究报告•2023年报及 2024 年一季报点评 当前价：37.33 元 百普赛斯（301080）医药生物 目标价：——元（6 个月） [Table_Summary 事件：公司发布] 2023年报及 2024年一季报，2023年公司实现收入 5.4亿元， 同比增长 14.6%；实现归母净利润 1.5 亿元，同比下降 24.6%；实现扣非归母 净利润 1.4亿元，同比下降 23.4%。2024年一季度公司实现收入 1.5 亿元，同 比增长 6.7%，实现归母净利润 0.3亿元，同比下降 31.9%，实现扣非归母净利 润 0.3 亿元，同比下降 32.1%。 海外业务持续高增长，国内业务增速稳定 海外常规业务高增，重组蛋白产品占比稳定。从区域来看，2023年公司扣除新 冠产品业务后实现收入 5亿元（+29.3%），其中海外地区常规业务收入 3.3亿元 （+37%）国内常规业务收入 1.7 亿元（+17%）。从产品类型来看，公司 2023 年重组蛋白实现收入 4.6亿元（+16%）。检测服务实现收入 0.16亿元（+4.3%）， 抗体、试 ...

Investment Rating - The investment rating for the company is "Accumulate" [18][16]. Core Views - The company achieved a revenue of 5.44 billion yuan in 2023, representing a year-on-year increase of 14.6%. Excluding specific acute respiratory disease-related products, the regular business revenue was 4.99 billion yuan, up 29.5% year-on-year [16][21]. - The overseas regular business revenue reached 3.30 billion yuan, growing by 37.1% year-on-year, while domestic regular business revenue was 1.69 billion yuan, an increase of 16.8% [16][21]. - The net profit attributable to the parent company was 1.54 billion yuan, down 24.6% year-on-year, primarily due to high-margin COVID-related product revenue in the previous year and increased expenses from team expansion [16][21]. - The company is set to launch its GMP-level production base in Suzhou in the second half of 2024, which will enhance its capacity for developing and producing GMP-grade biological reagents [16][21]. Financial Summary - The company's revenue is projected to reach 6.52 billion yuan in 2024, with a growth rate of 19.9%, and 7.78 billion yuan in 2025, with a growth rate of 19.4% [17]. - The net profit is expected to be 1.90 billion yuan in 2024 and 2.46 billion yuan in 2025, with a new forecast for 2026 net profit at 3.27 billion yuan [16][17]. - The current price-to-earnings (PE) ratios are projected to be 23x for 2024, 18x for 2025, and 14x for 2026 [16][18].

Investment Rating - The report maintains a "Buy" rating for the company [6]. Core Views - The company's conventional business continues to grow rapidly, with a revenue of 544 million yuan in 2023, representing a year-on-year increase of 14.59%. The net profit attributable to shareholders was 154 million yuan, down 24.61% [6][9]. - Significant increases in expenses have put short-term pressure on profits, with gross and net profit margins at 91.26% and 27.14%, respectively, in 2023 [7]. - The overseas business has shown impressive growth, with revenue from overseas conventional business reaching 330 million yuan, a year-on-year increase of 37.1% [8]. - The company has increased its R&D investment, spending 125 million yuan in 2023, which is a 9.72% increase from the previous year [8]. - The company has adjusted its profit forecasts for 2024 and 2025, expecting revenues of 658 million yuan and 816 million yuan, respectively, with corresponding net profits of 180 million yuan and 220 million yuan [9]. Summary by Sections Financial Performance - In 2023, the company achieved total revenue of 544 million yuan, with a growth rate of 14.59%. The net profit attributable to shareholders was 154 million yuan, reflecting a decline of 24.61% [6][12]. - For Q1 2024, the company reported revenue of 146 million yuan, a 6.67% increase, while net profit was 31 million yuan, down 31.91% [6][12]. Expense Analysis - The company's gross margin was 91.26%, down 1.24 percentage points, and the net margin was 27.14%, down 14.85 percentage points in 2023. The increase in expenses is attributed to expanded personnel and increased R&D investments [7][12]. Overseas Business Growth - The overseas conventional business generated 330 million yuan in revenue in 2023, marking a 37.1% increase. The Americas contributed 229 million yuan (up 29.8%), Europe 72 million yuan (up 69.5%), and Asia-Pacific 29 million yuan (up 33.4%) [8]. R&D Investment - The company invested 125 million yuan in R&D in 2023, a 9.72% increase, and expanded its R&D personnel to 247, an increase of 30.69% [8]. Profit Forecasts - The company has revised its profit forecasts, expecting revenues of 658 million yuan in 2024, 816 million yuan in 2025, and 1,001 million yuan in 2026, with net profits of 180 million yuan, 220 million yuan, and 272 million yuan, respectively [9][12].

公司快报 域 2024 年 4 月 23 日，公司发布 2023 年年度报告和 2024 年第一季度 报告。2023 年公司实现营业收入 5.44 亿元，同比增长 14.59%；实 现归母净利润 1.54 亿元，同比下滑 24.61%；实现扣非归母净利润 1.40 亿元，同比下滑 23.42%。2024 年 Q1 公司实现营业收入 1.46 亿元，同比增长 6.67%；实现归母净利润 0.31 亿元，同比下滑 31.91%；实现扣非归母净利润 0.30 亿元，同比下滑 32.12%。 常规业务保持高增长，海外市场表现亮眼。 | --- | --- | |--------------------------|------------------| | | 证券研究报告 | | | 生物医药Ⅲ | | 投资评级 | 买入-A 维持评级 | | 6 个月目标价 | 43.80 元 | | 股价 (2024-04-25) 37.02 | 元 | | | | | 交易数据 | | | 总市值(百万元 | ) 4,442.40 | | 流通市值(百万元 | ) 2,481.41 | | 总股本(百万股 | ) 120.0 ...